Acquisition And GrowthAytu BioPharma has acquired a transformative asset, EXXUA, which is expected to launch for major depressive disorder.
Financial PerformanceAytu reported F3Q25 results with total revenue of $18.5M, exceeding the estimate of $13.7M.
Product Launch PotentialA recently launched MDD therapy, Auvelity by Axsome Therapeutics, reached approximately $400M in sales within about 2.5 years, which is a positive indicator for EXXUA’s launch potential.